1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €11.22 (+42.03%). The median is €11.22 (+42.03%).
| Buy |
4 |
| Hold |
7 |
| Sell |
2 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 552.01K | 96.30% |
| Gross profit | 384.66K | 97.34% |
| Net profit | -4.24M | 309.15% |
| EBITDA | -4M | 231.18% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €72.95M |
Number of shares | 9.01M |
52-week high/low | €16.52 - €3.38 |
| Dividends | No |
Beta | 0.09 |
P/E ratio | -7.95 |
PEG ratio | 0.05 |
P/B ratio | -3.81 |
P/S ratio | 13.64 |
Company profile
| Name | Atara Biotherapeutics Inc |
| CEO | Anhco Nguyen |
| Employees | 10 |
Discover assets
Shareholders of Atara Biotherapeutics Inc also invest in the following assets
